Green Cross Corporation Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Osaka Japan (1950)
Status: Acquired by Welfide (1998) → now Mitsubishi Tanabe (2001)

Organization Overview

First Clinical Trial
2004
NCT01568580
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

GC Biopharma Corp | GC Biopharma Corp. | GC Cell Corporation | GC Pharma | Green Cross Cell Corporation | Green Cross Corporation | Green Cross LabCell Corporation | Green Cross Wellbeing | The Blood Plasma Corporation of Japan

Active Ingredients

Drugs in Phase 4 Trials (8)

acetylsalicylic acid (aspirin) (1 trial)

immune globulin (human) (Gamastan) (9 trials)

inactivated influenza vaccine (17 trials)

lactic acid (1 trial)

potassium chloride (klor-con) (1 trial)

rituximab (rituxan) (2 trials)

shinbaro (3 trials)

sodium chloride (4 trials)

Drugs in Phase 3 Trials (16)

antihemophilic factor viii human (Hemofil M) (1 trial)

antihemophilic factor viii (Recombinant) (Adynovate) (3 trials)

bacille calmette-guerin (2 trials)

celecoxib (celebrex) (2 trials)

Filgrastim (neupogen) (2 trials)

fluarix (1 trial)

gc1102 (5 trials)

gc1111 (2 trials)

gemcitabine (gemzar) (1 trial)

hantavax (2 trials)

hepatitis b immune globulin (human) (BayHep B) (2 trials)

human placenta hydrolysate (2 trials)

idursulfase (elaprase) (4 trials)

immuncell-lc (6 trials)

inactivated varicella vaccine (1 trial)

Tetanus and diphtheria toxoids adsorbed (Decavac) (2 trials)

Drugs in Phase 2 Trials (27)

acellular pertussis vaccine (including diptheria and tetanus toxoids) (Tripedia) (1 trial)

albumin (Human) (Plasbumin) (1 trial)

aldesleukin (Proleukin) (1 trial)

allogeneic natural killer cells (2 trials)

aluminum hydroxide (Gaviscon) (1 trial)

autologous t cells (1 trial)

crv-101 (1 trial)

cyclophosphamide (cytoxan) (1 trial)

diphtheria, tetanus and whole cell pertussis vaccine (Boostrix) (2 trials)

fludarabine (fludara) (1 trial)

fluorouracil (efudex) (1 trial)

folfirinox (1 trial)

gc3111 (1 trial)

gc5131 (1 trial)

human immunoglobulin g (1 trial)

irinotecan (Camptosar) (1 trial)

leucovorin (1 trial)

levoleucovorin (fusilev) (1 trial)

live attenuated varicella vaccine (Varivax) (2 trials)

lonicera japonica (1 trial)

mg1111 (3 trials)

mg4101 (1 trial)

Pegfilgrastim (1 trial)

rpa102 (1 trial)

suduvax (1 trial)

tramadol (Ultram) (1 trial)

varicella zoster virus glycoprotein e antigen (Shingrix) (1 trial)

Drugs in Phase 1 Trials (15)

agalsidase beta (Fabrazyme) (1 trial)

allogeneic hematopoietic stem cells (Hemacord) (2 trials)

apolipoprotein kringle v (1 trial)

crv 101 (1 trial)

darbepoetin alfa (aranesp) (1 trial)

epoetin (Epogen) (1 trial)

gc1109 (1 trial)

gc-1118 (1 trial)

gcc-4401 (2 trials)

linagliptin (tradjenta) (2 trials)

margetuximab (Margenza) (1 trial)

metformin (glucophage) (2 trials)

mg1113 (2 trials)

pexastimogene devacirepvec (1 trial)

rivaroxaban (xarelto) (1 trial)

Drugs in Other Trials (10)

bismuth (1 trial)

clarithromycin (biaxin) (1 trial)

lactobacillus plantarum (1 trial)

lactococcus lactis (1 trial)

maltodextrin (2 trials)

metronidazole (flagyl) (1 trial)

pantoprazole (protonix) (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

tetracycline (tetrex) (1 trial)

tivantinib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anthrax (Phase 2)

Ascites (Phase 4)

Bacterial Infections (Phase 3)

Breast Neoplasms (Phase 1)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Cerebral Infarction (Phase 2)

Chickenpox (Phase 1)

Colorectal Neoplasms (Phase 2)

Diphtheria (Phase 2)

Encephalitis (Phase 2)

Fabry Disease (Phase 1)

Fatigue (Phase 3)

Fatigue Syndrome, Chronic (Phase 3)

Gastritis (Phase 2)

Glioblastoma (Phase 3)

Hashimoto Disease (Phase 2)

Hemophilia A (Phase 3)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis B (Phase 3)

Hepatitis B, Chronic (Phase 2)

Hepatitis, Chronic (Phase 2)

Herpes Zoster (Phase 1)

Immunologic Deficiency Syndromes (Phase 3)

Infarction (Phase 2)

Influenza, Human (Phase 4)

Liver Neoplasms (Phase 1)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Mucocutaneous Lymph Node Syndrome (Phase 4)

Mucopolysaccharidoses (Phase 3)

Mucopolysaccharidosis II (Phase 3)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 1)

Neutropenia (Phase 3)

Osteoarthritis (Phase 4)

Osteoarthritis, Knee (Phase 2)

Pancreatic Neoplasms (Phase 2)

Purpura, Thrombocytopenic, Idiopathic (Phase 3)

Sepsis (Phase 3)

Shock (Phase 3)

Shock, Septic (Phase 3)

Stomach Neoplasms (Phase 1)

Syndrome (Phase 3)

Tetanus (Phase 2)

Tetany (Phase 2)

Thrombocytopenia (Phase 3)

Toxemia (Phase 3)

Tuberculosis (Phase 3)

Vaccinia (Phase 1)

Whooping Cough (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 101
  • # of Trial APIs: 76